• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Background The role of catheter ablation in patients with symptomatic atrial fibrillation and
end-stage heart failure is unknown. Methods We conducted a single-center, open-label trial …

In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based
safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007 …

MicroRNAs (miRNAs) are small regulatory molecules post-transcriptionally suppressing
mRNA activity. Many miRNAs in various organisms have been cloned but many unknown …

Pacemaker treatment for bradyarrhythmia was first approved for national health insurance
coverage in Japan in 1974, and its use rapidly became widespread thereafter …

Background: Even on optimal therapy, many patients with heart failure and atrial fibrillation
experience cardiovascular complications. Additional treatments are needed to reduce these …

Background Mortality and morbidity are higher among patients with atrial fibrillation and
heart failure than among those with heart failure alone. Catheter ablation for atrial fibrillation …

clinical guidelines, atrial fibrillation, ischemic stroke, anticoagulant therapy, vitamin K
antagonists, direct oral anticoagulants, triple antiplatelet therapy, rhythm control, electrical …

Background: Atrial fibrillation (AF) and heart failure (HF) frequently coexist and can be
challenging to treat. Pharmacologically based rhythm control of AF has not proven to be …